Literature DB >> 29019238

Total Synthesis and Anti-inflammatory Evaluation of Penchinone A and Its Structural Analogues.

Yongguk Oh1, Yeon Jeong Jang1, Mijin Jeon1, Hyung Sik Kim1, Jong Hwan Kwak1, Kyu Hyuck Chung1, Suhkneung Pyo1, Young Hoon Jung1,2, In Su Kim1.   

Abstract

The first total synthesis and biological evaluation of penchinone A and its structural analogues are described. The key steps for the preparation of penchinone A derivatives involve the oxime-directed palladium(II)-catalyzed oxidative acylation, Claisen rearrangement, and base-mediated olefin migration. This transformation efficiently provides a range of allyl-substituted biaryl ketones with site-selectivity and functional group compatibility. In addition, all synthetic compounds were screened for anti-inflammatory activity against nitric oxide (NO), tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6) with lipopolysaccharide (LPS)-induced RAW264.7 cells. Generally, a range of penchinone A derivatives potently inhibited NO, TNF-α, and IL-6 productions, compared to dexamethasone as a positive control. Notably, penchinone A (8g) and its derivatives (8e and 8f) were found to exhibit anti-inflammatory activity stronger than that of dexamethasone.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29019238     DOI: 10.1021/acs.joc.7b02212

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  2 in total

1.  Synthesis of TMPA Derivatives through Sequential Ir(III)-Catalyzed C-H Alkylation and Their Antidiabetic Evaluation.

Authors:  Suk Hun Lee; Amit Kundu; Sang Hoon Han; Neeraj Kumar Mishra; Kyeong Seok Kim; Myung Hoon Choi; Ashok Kumar Pandey; Jung Su Park; Hyung Sik Kim; In Su Kim
Journal:  ACS Omega       Date:  2018-03-06

2.  Relative Strength of Common Directing Groups in Palladium-Catalyzed Aromatic C-H Activation.

Authors:  Anna Tomberg; Michael Éric Muratore; Magnus Jan Johansson; Ina Terstiege; Christian Sköld; Per-Ola Norrby
Journal:  iScience       Date:  2019-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.